XML 39 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information and Concentration of Business Risk (Tables)
 12 Months Ended
Dec. 31, 2019
Segment Information and Concentration of Business Risk [Abstract]  
Segment Information

The following tables show our segment revenue and income (loss) from operations for 2019, 2018 and 2017 (in thousands), respectively.

2019
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
292,992
    
$
—
    
$
—
    
$
292,992
  
Product sales, net
    
—
      
42,253
      
—
      
42,253
  
Licensing and other royalty revenue
    
12,616
      
10,172
      
(5,583
)
    
17,205
  
Total commercial revenue
    
305,608
      
52,425
      
(5,583
)
    
352,450
  
R&D revenue under collaborative agreements
    
553,038
      
436,118
      
(219,007
)
    
770,149
  
Total segment revenue
  
$
858,646
    
$
488,543
    
$
(224,590
)
  
$
1,122,599
  
Total operating expenses
  
$
523,207
    
$
450,469
    
$
(216,960
)
  
$
756,716
  
Income (loss) from operations
  
$
335,439
    
$
38,074
    
$
(7,630
)
  
$
365,883
  

2018
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
237,930
    
$
—
    
$
—
    
$
237,930
  
TEGSEDI product sales, net
    
—
      
2,237
      
—
      
2,237
  
Licensing and other royalty revenue
    
2,755
      
12,000
      
—
      
14,755
  
Total commercial revenue
    
240,685
      
14,237
      
—
      
254,922
  
R&D revenue under collaborative agreements
    
401,259
      
50,630
      
(107,137
)
    
344,752
  
Total segment revenue
  
$
641,944
    
$
64,867
    
$
(107,137
)
  
$
599,674
  
Total operating expenses
  
$
380,212
    
$
295,683
    
$
(14,849
)
  
$
661,046
  
Income (loss) from operations
  
$
261,732
    
$
(230,816
)
  
$
(92,288
)
  
$
(61,372
)

2017
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
112,540
    
$
—
    
$
—
    
$
112,540
  
Licensing and other royalty revenue
    
7,474
      
—
      
—
      
7,474
  
Total commercial revenue
    
120,014
      
—
      
—
      
120,014
  
R&D revenue under collaborative agreements
    
405,171
      
43,401
      
(54,407
)
    
394,165
  
Total segment revenue
  
$
525,185
    
$
43,401
    
$
(54,407
)
  
$
514,179
  
Total operating expenses
  
$
373,788
    
$
163,871
    
$
(54,527
)
  
$
483,132
  
Income (loss) from operations
  
$
151,397
    
$
(120,470
)
  
$
120
    
$
31,047
  


The following table shows our total assets by segment at December 31, 2019 and 2018 (in thousands), respectively.


Total Assets
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
December 31, 2019
  
$
3,478,081
    
$
599,250
    
$
(844,219
)
  
$
3,233,112
  
December 31, 2018
  
$
2,975,491
    
$
365,261
    
$
(672,968
)
  
$
2,667,784